🇺🇸 FDA
Patent

US 12109196

Non-sedating dexmedetomidine treatment regimens

granted A61KA61K31/4174A61K47/10

Quick answer

US patent 12109196 (Non-sedating dexmedetomidine treatment regimens) held by BioXcel Therapeutics, Inc. expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioXcel Therapeutics, Inc.
Grant date
Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/4174, A61K47/10, A61K47/26, A61K47/34